Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement Disorders

June 25, 2015
APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson’s Disease TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced that it…

Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101

June 19, 2015
FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately…

Cynapsus Therapeutics Inc. Announces Pricing of US$63.0 Million Public Offering of Common Shares in the United States

June 18, 2015
TORONTO, ONTARIO -- Cynapsus Therapeutics Inc. (TSX:CTH)(OTCQX:CYNAD) (the "Company" or "Cynapsus") announced today the pricing of its underwritten public offering in the United States of 4,500,000 common shares at a…